Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reinke, R. Articles by Robinson, W. E. Search for Related Content PubMed PubMed Citation Articles by Reinke, R. Articles by Robinson, W. E., Jr.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2002, p. 3301-3303, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3301-3303.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Inhibition of Human Immunodeficiency Virus Type 1 Isolates by the Integrase Inhibitor L-731,988, a Diketo Acid

Ryan Reinke,¹ Deborah J. Lee,¹ and W. Edward Robinson Jr.^1,2*

Departments of Microbiology and Molecular Genetics,¹ Pathology, University of California, Irvine, California 92697²

Received 22 April 2002/ Returned for modification 19 June 2002/ Accepted 15 July 2002

Top Abstract Text References

 
L-731,988 inhibits human immunodeficiency virus (HIV) replication through integrase. In this study, approximately 600 nM L-731,988 inhibited the replication of 12 HIV type 1 isolates from multiple clades, including primary isolates and cloned viruses. These data suggest that diketo acids or their derivatives may prove useful on a worldwide basis in treating HIV infection.

Top Abstract Text References

 
The human immunodeficiency virus (HIV) genome encodes three enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN). Agents targeted at RT and PR inhibit viral replication within infected individuals (1, 2, 4). Despite the success of PR and RT inhibitors, recent evidence suggests that the transmission of drug-resistant HIV is increasing and that its rate of transmission can approach 25% (13), making it clear that new therapeutic targets must be identified. IN is an enzyme unique to retroviruses and is required for productive retroviral infection. Given the latter, as well as the clinical effectiveness of other retroviral enzyme inhibitors, IN is an attractive therapeutic target. Recently, the diketo acids were found to curb viral replication through the inhibition of IN (6). Amino acid changes that lead to resistance to diketo acids are located within IN and have been documented previously for HIV type 1 (HIV-1) (6). Analysis of the HIV sequence database shows that changes at 2 of the 3 amino acids conferring resistance to diketo acids are present within the infected population. To investigate the role that natural variation has in the susceptibility of HIV to diketo acids, a series of primary, cloned, and laboratory HIV-1 isolates were examined for susceptibility to L-731,988 (a diketo acid) (Fig. 1) in both cultured cell lines and peripheral blood lymphocytes (PBLs).

View larger version (9K): [in this window] [in a new window]

FIG. 1. Chemical structure of L-731,988.

Laboratory-adapted strains of HIV and the infectious molecular clone HIV_NL4-3 can replicate in cultured cell lines, unlike most primary isolates of HIV. Therefore, the susceptibilities to L-731,988 of laboratory-adapted strains (HIV_LAI and HIV_MVP5180) and HIV_NL4-3 clones containing different IN genes (HIV_NL4-3:IN7-3, HIV_NL4-3:INR104, HIV_NL4-3:INR106, and HIV_{NL4-3:IN92NG003}) were determined on cultured MT2 cells by using a vital dye assay (8, 10, 12).

HIV_LAI and HIV_NL4-3:IN7-3 are clade B, laboratory-adapted HIV strains that are susceptible to diketo acids (6; R. Reinke et al., unpublished data). Cloned isolates were constructed with HIV_NL4-3, which contains two unique restriction sites that allow the native IN to be excised and the IN gene of interest to be cloned in frame into the plasmid vector (7). HIV_NL4-3:IN7-3 contains the HIV_NL4-3 IN gene and was subjected to the same tissue culture and cloning procedures used for the other viruses (7) to control for changes due to culturing of virus and cloning. HIV_NL4-3:INR104 and HIV _NL4-3:INR106 contain IN genes derived from the North American clinical isolates described previously (9). HIV_{NL4-3:IN92NG003} contains an IN gene derived from a near-full-length clone of HIV originally isolated in Nigeria (3), and HIV_MVP5180 is a group O isolate from Cameroon (5). Nomenclature used throughout indicates the specific IN gene cloned into HIV_NL4-3: HIV_NL4-3:INR106 contains the IN gene from clinical isolate R106.

HIV-1 primary isolates (HIV_92RW016, HIV_92RW009, HIV_98IN026, HIV_93IN101, HIV_92THA005, HIV_98CN006) were obtained through the National Institutes of Health AIDS Research and Reference Reagent Program and passaged on phytohemagglutinin-stimulated PBLs with interleukin-2; each virus supernatant was collected when cultures exhibited peak staining with polyclonal anti-HIV serum by an immunofluorescence assay. Supernatants were filtered through 0.45-µm-pore-size filters and assayed for exogenous RT activity. Viral supernatants (36,000 cpm of RT activity) were incubated with 0, 0.5, 1.0, and 5.0 µM L-731,988 for 30 min at 37°C. Following incubation, viral supernatants were added to 1.5 x 10⁶ PBLs containing either 0, 0.5, 1.0, or 5.0 µM L-731,988 in a total volume of 2 ml. All infections were performed in triplicate in 24-well plates. Culture supernatants were monitored by indirect immunofluorescence assay and RT assay (11) every 2 days until RT activity within control infections without L-731,988 peaked. The percent inhibition at each drug concentration was calculated on the basis of the control infections. The 50% effective doses (ED₅₀) were calculated for the viruses when RT values for the control infections were at maximum. ED₅₀ were calculated using the CalcuSyn for Windows software package.

All six viruses tested in the MT2 cell assay were susceptible to the inhibitor, exhibiting only minor differences (two- to threefold) in ED₅₀ (Table 1). ED₅₀ for these isolates ranged from 0.5 to 1.6 µM. Similarly, the ED₅₀ of L-731,988 against the primary isolates ranged from 0.6 to 0.9 µM, with the exception of that for HIV_92RW009, which increased about sixfold compared to that for HIV_LAI (Table 1). Two assays were utilized in this study to examine the susceptibilities of natural variant IN sequences to L-731,988. Despite the differences between the two assays, the data for a control virus, HIV_LAI, correlate between the assays (Table 1) (0.51 to 0.65 µM), demonstrating that the antiviral data from both assays are directly comparable.

View this table: [in this window] [in a new window]

TABLE 1. Susceptibilities of HIV-1 isolates to L-731,988

The ability of compounds to inhibit primary isolates of HIV is of paramount importance in their development as drugs. The data presented here show that a group O isolate, group M primary viral isolates representing clades A, B, and C, and a clade A/E recombinant were all susceptible to L-731,988. Compared to the control HIV_LAI, most of these viruses exhibited a less-than-twofold difference in susceptibility to L-731,988. In contrast, the isolate HIV_92RW009, a C/A recombinant, showed an approximately sixfold decrease in susceptibility to L-731,988. While complete resistance was not observed, this partial-resistance phenotype was detected at all drug concentrations tested, as evidenced by less growth inhibition than with other viruses (Fig. 2). IN sequence analysis of HIV_92RW009 failed to reveal amino acid changes matching previously identified resistance mutations for either the diketo acid or the L-chicoric acid class of IN inhibitors (C65, T66, G140, S153, or M154) (6, 7, 14). These data suggest that other amino acid changes within the HIV_92RW009 IN may contribute to resistance to diketo acids. Amino acid changes unique to HIV_92RW009 IN were a valine-to-alanine change at position 79, a threonine-to-asparagine change at position 124, and a lysine-to-arginine change at position 173. However, the peak viral RT counts for the HIV_92RW009 cultures were greater than for other viruses tested. Thus, an increased burst size may contribute to the resistance phenotype.

View larger version (16K): [in this window] [in a new window]

FIG. 2. Representative susceptibilities of primary HIV isolates to L-731,988 in PBLs. PBLs were inoculated with HIV in the presence of 0.5, 1.0, or 5 µM L-731,988, and RT activity was measured. (A) Isolate HIV98CN006; (B) isolate HIV92RW009. Abbreviations: VC, virus control; DKA, diketo acid. Each point represents a mean of values from three independent infections, with error bars corresponding to 1 standard deviation.

To date, three mutations have been associated with resistance to the diketo acids: T66I, S153Y, and M154I (6). Two of the viruses tested contain amino acid changes at positions 153 and 154 of IN. Each virus had other mutations that could account for the resistance phenotype, but in particular, HIV_MVP5180 contains an S153A change and HIV_NL4-3:INR104 has an M154L change. HIV_MVP5180 does show an increase in ED₅₀ of roughly threefold, nearly identical to that observed by Hazuda et al. (6) for the S153Y mutation. Although S153 and M154 have been associated with resistance to diketo acids, the changes contained within HIV_MVP5180 and HIV_NL4-3:INR104 do not dramatically affect their susceptibility to L-731,988, suggesting that mutations occurring at these positions require additional changes, perhaps at position 66 (6), or specific amino acid substitutions for a high-resistance phenotype. Interestingly, S153Y conferred resistance to another diketo acid, L-708,906, but not to L-731,988 (6). It should be noted that if resistance occurs through the synergistic effect of mutations at positions 66, 153, and 154, as suggested by Hazuda et al. (6), the variability at positions 153 and 154 within the natural population may result in a more rapid development of resistance phenotypes. Nevertheless, 15% amino acid divergence for HIV_MVP5180 results in only a threefold decrease in susceptibility to L-731,988. Overall, these data suggest that naturally occurring genetic variation within the IN gene is not a major obstacle in the development of the diketo acids for therapeutic use.

Nucleotide sequence accession numbers The sequences of all IN genes reported herein have been deposited with GenBank. The accession numbers are R104-AF203330, R106-AF203331, 92NG003-U88825, 93IN101-AF500777, 98CN006-AF500778, 98IN026-AF500779, 92RW009-AF500780, 92RW016-AF500781, and 92THA005-AF500782.

 
This work was supported in part by grants from the Public Health Service (AI41360) and the Burroughs-Wellcome Fund (99-2609). W.E.R. is a Burroughs-Wellcome Fund Clinical Scientist in Translational Research. R.R. (grant AI07319) and D.J.L. (grant GM08620) are supported in part by training grants.

We are indebted to Brenda R. McDougall for excellent technical assistance. Manfred G. Reinecke (Texas Christian University, Fort Worth) provided L-731,988.

 
* Corresponding author. Mailing address: Department of Pathology, D440 Med. Sci. I, University of California, Irvine, CA 92697-4800. Phone: (949) 824-3431. Fax: (949) 824-2505. E-mail: ewrobins{at}uci.edu.

Top Abstract Text References

 

1
1. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116.[Abstract/Free Full Text]
2
2. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1011-1017.[Abstract/Free Full Text]
3
3. Gao, F., D. L. Robertson, C. D. Carruthers, S. G. Morrison, B. Jian, Y. Chen, F. Barré-Sinoussi, M. Girard, A. Srinivasan, A. G. Abimiku, G. M. Shaw, P. M. Sharp, and B. H. Hahn. 1998. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 72:5680-5698.[Abstract/Free Full Text]
4
4. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.[Abstract/Free Full Text]
5
5. Gürtler, L. G., P. H. Hauser, J. Eberle, A. von Brunn, S. Knapp, L. Zekeng, J. M. Tsague, and L. Kaptue. 1994. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68:1581-1585.[Abstract/Free Full Text]
6
6. Hazuda, D. J., P. Pelock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.[Abstract/Free Full Text]
7
7. King, P. J., and W. E. Robinson, Jr. 1998. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 72:8420-8424.[Abstract/Free Full Text]
8
8. Montefiori, D. C., W. E. Robinson, Jr., S. S. Schuffman, and W. M. Mitchell. 1988. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:231-235.[Abstract/Free Full Text]
9
9. Reinke, R., N. R. Steffen, and W. E. Robinson, Jr. 2001. Natural selection results in conservation of HIV-1 integrase activity despite sequence variability. AIDS 15:823-830.[CrossRef][Medline]
10
10. Robinson, W. E., Jr., M. Cordeiro, S. Abdel-Malek, Q. Jia, S. A. Chow, M. G. Reinecke, and W. M. Mitchell. 1996. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmacol. 50:846-855.[Abstract]
11
11. Robinson, W. E., Jr., D. C. Montefiori, D. H. Gillespie, and W. M. Mitchell. 1989. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquir. Immune Defic. Syndr. 2:33-42.
12
12. Robinson, W. E., Jr., M. G. Reinecke, S. Abdel-Malek, Q. Jia, and S. A. Chow. 1996. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. USA 93:6326-6331.[Abstract/Free Full Text]
13
13. Wegner, S. A., S. K. Brodine, J. R. Mascola, S. A. Tasker, R. A. Shaffer, M. J. Starkey, A. Barile, G. J. Martin, N. Aronson, W. W. Emmons, K. Stephan, S. Bloor, J. Vingerhoets, K. Hertogs, and B. Larder. 2000. Prevalence of genotypic and phenotypic resistance to antiretroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 14:1009-1015.[CrossRef][Medline]
14
14. Zhu, K., M. L. Cordeiro, J. Atienza, W. E. Robinson, Jr., and S. A. Chow. 1999. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J. Virol. 73:3309-3316.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, October 2002, p. 3301-3303, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3301-3303.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G., Jochmans, D., Vermeire, K., Schols, D., Hallenberger, S., Hertogs, K. (2008). Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. J. Virol. 82: 10366-10374 [Abstract] [Full Text]  
• Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., Matsuoka, M. (2008). Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J. Virol. 82: 764-774 [Abstract] [Full Text]  
• Gillim-Ross, L., Cara, A., Klotman, M. E. (2005). Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. J. Gen. Virol. 86: 765-771 [Abstract] [Full Text]  
• Lee, D. J., Robinson, W. E. Jr. (2004). Human Immunodeficiency Virus Type 1 (HIV-1) Integrase: Resistance to Diketo Acid Integrase Inhibitors Impairs HIV-1 Replication and Integration and Confers Cross-Resistance to L-Chicoric Acid. J. Virol. 78: 5835-5847 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reinke, R. Articles by Robinson, W. E. Search for Related Content PubMed PubMed Citation Articles by Reinke, R. Articles by Robinson, W. E., Jr.